Table 4.
Results from cardiac magnetic resonance imaging
| Placebo (n = 32) |
Rosiglitazone (n = 43) |
P-value between groups at end-of-study | |||||
|---|---|---|---|---|---|---|---|
| Baseline | End-of-study | P-value within group | Baseline | End-of-study | P-value within group | ||
| End systolic volume, mL | 39.9 (12) | 39.1 (13.5) | 0.63 | 43.0 (18.3) | 44.4 (18.7) | 0.47 | 0.28 |
| End diastolic volume, mL | 114.8 (18.9) | 112 (24.4) | 0.34 | 117.9 (26.9) | 128.1 (25.6) | 0.001 | 0.01 |
| Ejection fraction, % | 65.4 (7.6) | 65.9 (6.8) | 0.70 | 63.8 (10.7) | 66.1 (9.8) | 0.03 | 0.90 |
| LV mass index, g/m2 | 76.9 (18.0) | 75.2 (14.3) | 0.28 | 85.9 (21.5) | 83.2 (22.7) | 0.14 | 0.06 |
| Stroke volume, mL | 74.8 (13.8) | 72.9 (15.4) | 0.36 | 74.9 (21.2) | 83.7 (20) | 0.0004 | 0.01 |
| Peak filling rate, mL/s | 68.1 (42.5) | 60.5 (24.9) | 0.37 | 70.8 (32.6) | 79.4 (41.9) | 0.38 | 0.07 |
All values reported as means (SD).